



Practice Aid

# Rational Design of ADC Components

Site-specific conjugation


- Engineered cysteine
- Enzymatic conjugations
- Incorporation of UAAs

Conjugation through lysine or cysteine residues

Noncleavable  
Lysosomal degradation to release drugs

Cleavable

- Acid-sensitive
- Lysosome protease-sensitive
- Redox-sensitive



Target microtubules

- Auristatin derivatives
- Maytansinoids
- Tubulysins

Target DNA

- Calicheamicins analogues
- Duocarmycin analogues

ADC: antibody drug-conjugate; UAA: unnatural amino acid.  
 Zhao P et al. *Acta Pharm Sin B*. 2020;10:1589-1600.

The information presented here is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment included here should not be used by clinicians without evaluation of their patients' conditions and possible contraindications, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

No endorsement of any products or uses is made or implied by coverage of such in our materials. No responsibility is taken for errors or omissions in our materials.